HS Code:
4-Chlorophenylglycine (CAS No. 6212-33-5) is an organic compound classified under HS Code 2922.49.30, which falls within the broader category of oxygen-function amino-compounds, specifically amino-acids and their esters. This chemical is primarily used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. It plays a critical role in the production of active pharmaceutical ingredients (APIs) for drugs targeting various medical conditions. The compound is a derivative of glycine with a chlorophenyl group, making it valuable for its specific chemical reactivity and applications in chiral synthesis.
Total Trade Volume
Approximately $15 million USD
Data from 2022
Source
UN Comtrade Database, International Trade Centre (ITC)
$6.5 million USD
43.3% of total trade of total trade
Increasing
$3.2 million USD
21.3% of total trade of total trade
Increasing
$1.8 million USD
12.0% of total trade of total trade
Stable
$1.5 million USD
10.0% of total trade of total trade
Stable
$1.0 million USD
6.7% of total trade of total trade
Decreasing
Average Rate
5.5% ad valorem
Highest Rate
10% (applied by certain developing countries)
Lowest Rate
0% (under free trade agreements such as EU-Japan EPA)
Rising demand for pharmaceutical intermediates
Increased production and export from China and India due to growing generic drug manufacturing globally.
2021-2022
Shift towards sustainable production
Pressure on manufacturers to adopt green chemistry practices, potentially increasing production costs but improving market access in eco-conscious regions like the EU.
2022
Supply chain diversification
Post-COVID-19, importing countries are seeking alternative suppliers outside China to mitigate risks of supply disruptions.
2020-2022
The European Union updated its REACH regulations, requiring more detailed documentation for chemical intermediates like 4-Chlorophenylglycine to ensure safety and environmental compliance.
June 2023
Increased compliance costs for exporters to the EU, potentially reducing trade volumes from non-compliant suppliers.
Under the 'Atmanirbhar Bharat' initiative, India has incentivized domestic production of pharmaceutical intermediates, including 4-Chlorophenylglycine, to reduce reliance on Chinese imports.
March 2022
Strengthened India's position as a key exporter, potentially shifting trade patterns in favor of Indian suppliers.
Ongoing trade disputes have led to additional tariffs on Chinese chemical exports to the US, impacting the cost competitiveness of 4-Chlorophenylglycine.
January 2023
Encouraged US importers to explore alternative suppliers in India and Europe, diversifying supply chains.